Kestra Medical Advances Q1 Results, Raises FY27 Revenue Guidance
Kestra reported F1Q27 revenue of $31.0M, up 60% year over year, with a gross margin of 56.5%. Management raised FY27 revenue guidance to $141M, signaling durable demand from the WCD market and in-network patients. Net liquidity remains robust (~$320M including committed loan availability), though GAAP net loss persisted, highlighting ongoing investment in commercialization and R&D.
View signal analysis